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ORIGINAL RESEARCH ARTICLE
Prioritizing the Role of Major Lipoproteins and 
Subfractions as Risk Factors for Peripheral  
Artery Disease
Michael G. Levin, MD*; Verena Zuber , PhD*; Venexia M. Walker, PhD; Derek Klarin , MD; Julie Lynch, PhD;  
Rainer Malik, PhD; Aaron W. Aday , MD, MSc; Leonardo Bottolo, PhD; Aruna D. Pradhan, MD, MPH;  
Martin Dichgans , MD; Kyong-Mi Chang, MD; Daniel J. Rader, MD; Philip S. Tsao, PhD; Benjamin F. Voight , PhD;  
Dipender Gill, BMBCh, PhD†; Stephen Burgess, PhD†; Scott M. Damrauer , MD†; on behalf of the VA Million Veteran Program 
BACKGROUND: Lipoprotein-related traits have been consistently identified as risk factors for atherosclerotic cardiovascular 
disease, largely on the basis of studies of coronary artery disease (CAD). The relative contributions of specific lipoproteins to 
the risk of peripheral artery disease (PAD) have not been well defined. We leveraged large-scale genetic association data to 
investigate the effects of circulating lipoprotein-related traits on PAD risk.
METHODS: Genome-wide association study summary statistics for circulating lipoprotein-related traits were used in the 
mendelian randomization bayesian model averaging framework to prioritize the most likely causal major lipoprotein and 
subfraction risk factors for PAD and CAD. Mendelian randomization was used to estimate the effect of apolipoprotein B 
(ApoB) lowering on PAD risk using gene regions proxying lipid-lowering drug targets. Genes relevant to prioritized lipoprotein 
subfractions were identified with transcriptome-wide association studies.
RESULTS: ApoB was identified as the most likely causal lipoprotein-related risk factor for both PAD (marginal inclusion 
probability, 0.86; P=0.003) and CAD (marginal inclusion probability, 0.92; P=0.005). Genetic proxies for ApoB-lowering 
medications were associated with reduced risk of both PAD (odds ratio,0.87 per 1-SD decrease in ApoB [95% CI, 0.84–
0.91]; P=9×10−10) and CAD (odds ratio,0.66 [95% CI, 0.63–0.69]; P=4×10−73), with a stronger predicted effect of ApoB 
lowering on CAD (ratio of effects, 3.09 [95% CI, 2.29–4.60]; P<1×10−6). Extra-small very-low-density lipoprotein particle 
concentration was identified as the most likely subfraction associated with PAD risk (marginal inclusion probability, 0.91; 
P=2.3×10−4), whereas large low-density lipoprotein particle concentration was the most likely subfraction associated with 
CAD risk (marginal inclusion probability, 0.95; P=0.011). Genes associated with extra-small very-low-density lipoprotein 
particle and large low-density lipoprotein particle concentration included canonical ApoB pathway components, although 
gene-specific effects were variable. Lipoprotein(a) was associated with increased risk of PAD independently of ApoB (odds 
ratio, 1.04 [95% CI, 1.03–1.04]; P=1.0×10−33).
CONCLUSIONS: ApoB was prioritized as the major lipoprotein fraction causally responsible for both PAD and CAD risk. However, 
ApoB-lowering drug targets and ApoB-containing lipoprotein subfractions had diverse associations with atherosclerotic 
cardiovascular disease, and distinct subfraction-associated genes suggest possible differences in the role of lipoproteins in 
the pathogenesis of PAD and CAD.
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A therosclerotic cardiovascular disease (ASCVD) is the most common cause of morbidity and mortality worldwide.1 Most research has 
focused on ASCVD in the coronary arteries (coro-
nary artery disease [CAD]). However, peripheral 
artery disease (PAD) represents another common 
and often underrecognized manifestation of ASCVD 
that is also associated with significant morbidity (eg, 
pain, tissue loss, amputation) and mortality, affecting 
>5% of the global adult population.2,3 Dyslipidemia 
has been a long-established risk factor for ASCVD, 
with the strongest evidence derived from large stud-
ies focused primarily on CAD end points. Although 
low-density lipoprotein (LDL) cholesterol (LDL-C)–
reducing medications such as statins are commonly 
used in the prevention and treatment of PAD, evidence 
for the relationship between LDL-C and PAD risk has 
been inconsistent.4 Observational studies with modest 
event rates have suggested that components of the 
atherogenic dyslipidemia profile (elevated levels of tri-
glyceride-rich lipoproteins, small LDL-C, and the ratio 
of total cholesterol to high-density lipoprotein choles-
terol [HDL-C], along with low concentrations of HDL-
C) may be more strongly associated with PAD than 
CAD, although the relative contribution of the major 
circulating lipoproteins (LDL-C, HDL-C, triglycerides, 
apolipoprotein B [ApoB], and apolipoprotein A1) and 
associated lipoprotein subfractions to PAD specifically 
has remained poorly defined.4–7
Over the past 15 years, genome-wide association 
studies (GWASs) have identified hundreds of genetic 
loci associated with ASCVD traits, major lipoproteins, 
and related subfractions.8–12 The large data sets aris-
ing from these studies include genetic associations 
estimated in hundreds of thousands of participants. An 
array of analytical methods enable the analysis of these 
genetic data sets to provide insights into the underly-
ing biology of diseases. Mendelian randomization (MR) 
uses genetic variants as instrumental variables to infer 
the effect of an exposure on an outcome, under the 
assumption that genetic associations with the outcome 
are mediated via the exposure for selected variants.13 
MR has been used to implicate ApoB as an important 
risk factor for CAD and to validate the effects of drug 
targets on disease outcomes.14–19 Integrating genetic 
data with gene transcription data sets in transcriptome-
wide association studies (TWASs) has been used to 
identify tissue-level gene expression associations with 
disease (such as between hepatic expression of SORT1 
and risk of CAD).20
We aimed to integrate large-scale genetic data sets 
(1) to prioritize the role of circulating lipoproteins and 
subfractions on PAD risk, (2) to identify genes that may 
Clinical Perspective
What Is New?
• Apolipoprotein B was identified as the most likely 
casual lipoprotein-related risk factor for periph-
eral artery disease (PAD), and apolipoprotein B 
(ApoB)–lowering medications were predicted to 
reduce the risk of PAD.
• The effect of ApoB (and ApoB-lowering medica-
tions) was predicted to be ≈3 times greater for 
coronary artery disease than PAD.
• Extra-small very-low-density lipoprotein was pri-
oritized as the most likely ApoB-containing sub-
fraction associated with PAD risk, whereas large 
low-density lipoprotein particle concentration was 
prioritized as the most likely subfraction associated 
with coronary artery disease.
What Are the Clinical Implications?
• Interventions targeting ApoB are likely to reduce 
the risk of PAD.
• Future studies may be warranted to test whether 
interventions targeting specific lipoprotein-related 
subfractions may reduce the risk of PAD and coro-
nary artery disease.
Nonstandard Abbreviations and Acronyms
ApoB apolipoprotein B
ASCVD  atherosclerotic cardiovascular 
disease
CAD coronary artery disease
CETP cholesteryl ester transfer protein
FDR false discovery rate
GWAS genome-wide association study
HDL-C  high-density lipoprotein cholesterol
L.LDL.P  large low-density lipoprotein particle 
concentration
LDL-C low-density lipoprotein cholesterol
Lp(a) lipoprotein(a)
MR mendelian randomization
MR-BMA  mendelian randomization bayesian 
model averaging
MVP  Veterans Affairs Million Veteran 
Program
NMR nuclear magnetic resonance
OR odds ratio
PAD peripheral artery disease
PHS Physicians’ Health Study
TWAS  transcriptome-wide association 
study
VLDL very-low-density lipoprotein
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represent novel lipoprotein-pathway targets in the pre-
vention and treatment of PAD, and (3) to estimate the 




The data that support the findings of this study are available 
from the corresponding author on reasonable request. GWAS 
summary statistics for PAD are available by application in dbGaP 
(phs001672). GWAS summary statistics for Global Lipids 
Genetics Consortiumlipids, UK Biobank lipids, nuclear magnetic 
resonance (NMR) lipids, and CARDIoGRAMplusC4D CAD are 
available for download from the Integrative Epidemiology Unit 
Open GWAS Project.
Ethics Approval
The Veterans Affairs Central Institutional Review Board 
approved the MVP (Million Veteran Program) study protocol.
Study Population and Outcomes
Our primary outcome was PAD. Genetic associations with 
PAD were derived from a 2019 GWAS by Klarin et al.10 
Full summary data are available by application to dbGaP 
(phs001672). This study included 31 307 PAD cases (24 009 
European ancestry, 5373 African ancestry, 1925 Hispanic 
ancestry) and 211 753 controls among participants of the 
Veterans Affairs MVP, which recruited individuals 19 years of 
age from Veterans Affairs medical centers across the United 
States.21 PAD diagnoses were ascertained from electronic 
health records using International Classification of Diseases 
9th and 10th revision and Current Procedural Terminology 
codes. Genetic associations were performed separately by 
ancestry groups with logistic regression adjusted for age, 
sex, and 5 ancestry-specific genetic principal components 
and then combined using an inverse-variance weighted fixed-
effects method.
CAD was included as an outcome in our analysis to help 
contextualize the PAD results because most of the obser-
vational, MR, and randomized control trial data relating to 
ASCVD have focused on CAD outcomes. Genetic associa-
tions with CAD were derived from the CARDIoGRAMplusC4D 
1000 Genomes GWAS.11 This is a meta-analysis of 48 stud-
ies, including 60 801 CAD cases and 123 504 controls of 
European ancestries (77%), including combination incident 
and prevalent CAD among the cases. CAD case/control sta-
tus was determined at the individual study level, with CAD 
cases included on the basis of the presence of myocardial 
infarction, acute coronary syndrome, chronic stable angina, or 
coronary stenosis of >50%.
Prioritizing the Role of Major Lipoprotein-
Related Traits and Lipoprotein Subfractions  
on PAD
We performed 2 MR bayesian model averaging (MR-BMA)14 
analyses as illustrated in Figure 1A. MR-BMA is an extension 
of multivariable MR that applies a bayesian variable selection 
method and aims to identify true causal risk factors (rather 
than the magnitude of effect) by jointly considering correlated 
exposures (in this case, lipoprotein-related traits).14,22,23 Details 
of the MR-BMA method are available in Methods in the Data 
Supplement. First, to identify causal relationships between 
major lipoprotein-related traits and PAD, our exposures of inter-
est were circulating lipoproteins (LDL-C, HDL-C), their primary 
constituent apolipoproteins (apolipoprotein A1 and ApoB), and 
triglycerides (Figure 1A). Second, to investigate whether the 
predicted effect of ApoB lowering on PAD may be influenced 
by specific lipoprotein subfractions, we performed a further 
MR-BMA analysis focusing on 10 ApoB-containing lipoprotein 
subfractions (Figure 1A). For comparison, we also performed 
these analyses for CAD.
The instrumental variables consisted of 145 independent 
(r2<0.001 in the 1000 Genomes European-ancestry Reference 
Panel) genetic variants associated with any major lipoprotein-
related trait (total cholesterol, LDL-C, HDL-C, or triglycerides) 
at a genome-wide significance level (P<5×10−8) in the Global 
Lipids Genetics Consortium GWAS, an analysis comprising 60 
individual studies of primarily European-ancestry participants.8 
Genetic associations with circulating levels of major lipoprotein-
related traits in blood were estimated in the UK Biobank study 
based on 361 194 European-ancestry participants. Genetic 
associations were adjusted for age, sex, and 20 principal com-
ponents. Genetic associations with lipoprotein subfractions were 
estimated from a GWAS of circulating lipoproteins and subfrac-
tions in 24 925 European-descent participants.9 In this data set, 
lipoproteins and subfractions were measured with NMR spec-
troscopy. Genetic associations were adjusted for age, sex, and 
the first 10 genetic principal components. As a replication analy-
sis, we repeated the analysis for major lipoprotein-related traits 
using genetic associations from the NMR data set.
Transcriptome-Wide Association Study
After prioritizing the role of lipoprotein subfractions in PAD, 
we next sought to identify genes associated with those sub-
fractions, which may ultimately serve as therapeutic targets 
(Figure 1B). To identify genes associated with circulating lev-
els of lipoprotein subfractions, TWASs were performed using 
S-PrediXcan.20 This tool enables the integration of tissue-
level expression quantitative trait loci data sets with GWAS 
summary statistics to prioritize genes associated with traits 
of interest. Because the liver plays a critical role in lipopro-
tein metabolism, we obtained a pretrained transcriptome 
prediction model for liver gene expression derived from the 
Genotype-Tissue Expression Project version 8. Predicted liver 
gene expression and GWAS summary statistics for lipopro-
tein subfractions were then correlated using S-PrediXcan to 
identify genes significantly associated with circulating levels 
of lipoprotein subfractions. The significance of differences in 
the effect of each gene on each outcome was determined by 
z Effect Effect SE SEdiff XS VLDL P L LDL P XS VLDL P L LDL= −[ ] +. . . . . . ./ 2 . ,P2  
with P values derived from the normal distribution. We per-
formed gene ontology enrichment analysis using ShinyGO 
to identify Gene Ontology Biological Processes significantly 
associated with the genes prioritized by S-PrediXcan.24 Finally, 
we performed a combined multivariate and collapsing test to 
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prioritized by the TWAS on risk of PAD among participants 
of the UK Biobank who underwent whole-exome sequencing 
(Methods in the Data Supplement).25
Genetically Proxied ApoB Lowering and PAD 
Risk
To predict the impact of ApoB lowering on PAD and CAD risk, 
we performed further MR analyses (Figure 1C). We performed 
gene-based analyses using variants associated with ApoB in 
gene regions that proxy specific lipid-lowering drugs (licensed 
or proposed) and polygenic analyses using all such variants. 
Genetic variants associated with ApoB levels at genome-wide 
significance (P<5×10−8) were identified from the UK Biobank 
and pruned at r2<0.1 to exclude highly correlated variants. This 
set of variants was further narrowed into 2 biologically informed 
sets. First, we examined variants located in or near (±200 kb) 
genes encoding previously identified regulators of ApoB metab-
olism (ABCG5/8, ANGPTL3, ANGPTL4, ANGPTL8, APOC3/
APOA5, APOB, CETP, DGAT, HMGCR, LDLR, LPL, MTTP, 
NPC1L1, PCSK9, and PPARA), representing the targets of cur-
rent or proposed therapeutics.16 Next, we examined variants in 
or near (±200 kb) genes associated with extra-small very-low-
density lipoprotein (VLDL) particle concentration (XS.VLDL.P) 
in the TWAS analysis (false discovery rate [FDR] q<0.05).26 
Genetic associations with ApoB were taken from the NMR data 
set to avoid winner’s curse and sample overlap.9 MR estimates 
were obtained from the random-effects inverse variance–
weighted method performed using the MendelianRandomization 
package in R, accounting for linkage disequilibrium correlation 
among variants using the 1000 Genomes Phase 3 European 
reference panel. The MR-Egger method, which makes differ-
ent assumptions about the presence of pleiotropy at the cost 
of decreased statistical power, was performed as a sensitivity 
analysis when >2 single nucleotide polymorphisms were pres-
ent in the genetic instrument.27
Lipoprotein(a) and PAD Risk
To examine the relationship between lipoprotein(a) Lp(a) and 
PAD, we performed 2-sample MR using summary statistics. As 
genetic instruments for Lp(a), we used 15 common genetic 
variants that are conditionally independent predictors of Lp(a), 
had previously been shown to explain >40% of the variance in 
circulating Lp(a) levels, and were present in GWAS summary 
statistics for both PAD and CAD. We obtained genetic associa-
tion effect estimates from a previous analysis.28 We performed 
inverse variance–weighted MR, considering PAD as the pri-
mary outcome, with CAD presented for comparison. We also 
performed multivariable MR, accounting for the associations 
between these genetic variants and ApoB in the UK Biobank 
biomarker GWAS.
Statistical Analysis
For the main MR-BMA analyses of major lipoprotein-related 
traits and PAD, FDR correction was performed to account for 
multiple testing, with FDR-corrected q<0.05 set as the pre-
determined significance threshold.15 For the MR-BMA analysis 
of lipoprotein subfractions, the Nyholt procedure of effective 




Figure 1. Overview of risk factor prioritization, drug target, and transcriptome-wide association study (TWAS) analyses.
Overview of main analyses. A, Risk factor prioritization was performed with mendelian randomization (MR) bayesian model averaging to prioritize 
the contribution of major lipoproteins and apolipoprotein (Apo) B–containing subfractions to peripheral artery disease (PAD) and coronary artery 
disease (CAD) risk. The primary MR assumptions are denoted, with red dashed lines representing violations of the MR assumptions. B, A TWAS 
integrating gene expression and genetic association data was performed to identify putative genes involved in the regulation of the prioritized 
ApoB-containing subfractions. C, Drug target MR was performed to identify the effect of genes encoding targets of ApoB-lowering medications 
on PAD and CAD outcomes. FDR indicates false discovery rate; HDL-C, high-density lipoprotein cholesterol; IDL.P, intermediate-density 
lipoprotein particles; L.LDL.P, large large-density lipoprotein particles; L.VLDL.P, large very-large-density lipoprotein particles; M.LDL.P, medium 
large-density lipoprotein particles; M.VLDL.P, medium very-large-density lipoprotein particles; NMR, nuclear magnetic resonance; PAD, peripheral 
artery disease; S.LDL.P, small large-density lipoprotein particles; SNP, single nucleotide polymorphism; S.VLDL.P, small very-large-density 
lipoprotein particles; XL.VLDL.P, extralarge very-large-density lipoprotein particles; XS.VLDL.P, extra-small very-large-density lipoprotein particles; 
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subfractions, with a multiple testing–adjusted value of P=0.05 
set as the significance threshold.29 For the drug target MR anal-
ysis, P<0.05 was the predetermined significance threshold. For 
the TWAS and gene ontology enrichment analyses, the FDR 
was used to account for multiple testing, with FDR-corrected 
P<0.05 set as the predetermined significance threshold. To 
compare the influence of lipoprotein risk factors on PAD versus 
CAD, we calculated the ratio of effects (log-odds), with 95% 
CIs obtained by bootstrap resampling. All statistical analy-
ses were performed with R version 4.0.3 (R Foundation for 
Statistical Computing). This study is reported in accordance 
with the Strengthening the Reporting of Observational Studies 
in Epidemiology guidelines for reporting observational studies.30
RESULTS
Prioritizing the Role of Major Lipoprotein-
Related Traits and Lipoprotein Subfractions on 
PAD
In the MR-BMA analysis for major lipoprotein-related 
traits, ApoB was the top-ranked risk factor for PAD (mar-
ginal inclusion probability, 0.86; P=0.003; Table 1 and 
Tables I–III in the Data Supplement). In the replication 
analysis, in which genetic association estimates for the 
5 major lipoprotein-related traits were derived from the 
NMR metabolite GWAS, ApoB was again the top-ranked 
risk factor for PAD with a marginal inclusion probability 
of 0.68 (P=0.001; Tables IV–VI in the Data Supplement). 
Similarly, ApoB was identified as the prioritized risk fac-
tor for CAD in the primary (marginal inclusion probability, 
0.92; P=0.005; Table 1) and replication (marginal inclu-
sion probability, 0.80; P=0.004) analyses, in keeping with 
the previously established role of ApoB in CAD (Tables 
VII and VIII in the Data Supplement).15,16 These results 
provide strong, consistent support for the role of ApoB 
as the primary lipoprotein risk factor for PAD and CAD.
In the MR-BMA analysis for lipoprotein subfractions, 
XS.VLDL.P was prioritized as the primary ApoB-contain-
ing risk factor for PAD (marginal inclusion probability, 
0.91; P=2.3×10−4; Table 2 and Table IX in the Data Sup-
plement). In contrast, large LDL particle concentration 
(L.LDL.P) was prioritized as the primary ApoB-containing 
risk factor for CAD (marginal inclusion probability, 0.95; 
P=0.011; Table 2 and Table X in the Data Supplement).
Identification of Genes Associated With ApoB-
Containing Lipoprotein Subfractions
Having prioritized XS.VLDL.P and L.LDL.P as important 
ApoB-containing lipoprotein subfractions for PAD and CAD, 
respectively, we explored whether specific genes may influ-
ence the circulating levels of these subfractions. Given the 
key role of the liver in lipoprotein metabolism, we integrated 
hepatic gene expression data from the Genotype-Tissue Ex-
pression Project with the XS.VLDL.P and L.LDL.P GWAS 
summary statistics to identify genes associated with circulat-
ing levels of each ApoB-containing lipoprotein subfraction.
Using TWAS, we identified 31 genes associated with 
XS.VLDL.P and 23 genes associated with L.LDL.P, for a 
total of 40 unique genes (FDR <0.05 for either subfrac-
tion; Tables XI and XII in the Data Supplement). Of these 
40 genes, 17 were uniquely associated with XS.VLDL.P 
levels, 9 were uniquely associated with L.LDL.P levels, 
and 14 were associated with circulating levels of both 
subfractions (Figure 2A and 2B). As expected, genes 
associated with these lipoprotein subfractions were 
significantly enriched for membership in cholesterol 
metabolism and related pathways (Table XIII in the Data 
Supplement). Among the genes associated with both 
subfractions were several canonical genes involved in 
lipoprotein metabolism, including PCSK9, ABCG8, LIPC, 
and APOA5. The 17 genes uniquely associated with 
XS.LDL.P levels were enriched for clusters of biological 
processes involving triglyceride-rich lipoprotein metabo-
lism (Table XIV in the Data Supplement), whereas the 9 
genes uniquely associated with L.LDL.P levels were not 
significantly enriched for specific biological processes.
Across the genome, there was overall a strong corre-
lation between the estimated effects of gene expression 
on circulating XS.VLDL.P and L.LDL.P levels (Pearson 
correlation=0.80, P<2.2×10−16). However, among the 
40 genes significantly associated with either lipopro-
tein subfraction, we identified potentially heterogeneous 
effects. For example, NLRC5, LIPC, CETP, APOA5, 
USP1, ANGPTL3, and ATGC4 expression was predicted 
to more strongly affect circulating XS.VLDL.P levels 
compared with L.LDL.P (Figure 2C).









 ApoB 0.856 0.003 0.015
 ApoA1 0.529 0.025 0.052
 HDL-C 0.467 0.031 0.052
 LDL-C 0.461 0.168 0.21
 Triglycerides 0.238 0.386 0.386
CAD
 ApoB 0.922 0.005 0.027
 HDL-C 0.457 0.022 0.054
 LDL-C 0.33 0.746 0.746
 ApoA1 0.284 0.123 0.206
 Triglycerides 0.152 0.58 0.726
Ranking of most likely causal exposures among major lipoproteins for PAD 
and CAD was performed with multivariable mendelian randomization in the men-
delian randomization bayesian model averaging framework. FDR-corrected P 
values are derived in an empirical permutation procedure. Apo indicates apo-
lipoprotein; CAD, coronary artery disease; FDR, false discovery rate; HDL-C, 
high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; 
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To investigate the impact of these genes on PAD risk, 
we examined whether damaging mutations in XS.VLDL.P–
associated genes might influence PAD risk among UK 
Biobank participants. We identified rare loss-of-function 
variants in 29 of 31 XS.VLDL.P–associated genes among 
154 584 UK Biobank participants (1668 PAD cases and 
152 916 controls). After multiple testing was accounted for, 
only damaging variants in SP4 were associated with preva-
lent PAD (FDR q=0.049; Table XV in the Data Supplement).
Genetically Predicted ApoB Lowering and PAD 
Risk
Because MR has previously been used to predict the im-
pact of current and proposed ApoB-lowering therapies 
on CAD risk, we sought to explore the effect of these 
treatments on PAD risk.16 We first performed polygen-
ic and gene-based MR analyses to determine whether 
ApoB-associated genetic variants located within/near 
genes encoding these therapeutic targets were associ-
ated with risk of PAD. In polygenic analyses, genetically 
proxied ApoB lowering was associated with reduced 
risk of PAD (odds ratio [OR], 0.87 per 1-SD reduction in 
ApoB [95% CI, 0.84–0.91]; P=9×10−9; Figure 3A). As a 
comparison, the association of genetically proxied ApoB 
lowering with CAD risk using the same genetic variants 
was greater (OR, 0.66 per 1-SD decrease in circulating 
ApoB [95% CI, 0.63–0.69], P=4×10−73; ratio of effects, 
3.09 [95% CI, 2.29–4.60], P<1×10−6). Associations 
were also significant with the MR-Egger method (PAD 
OR, 0.91 [95% CI, 0.86–0.98], P=0.009; CAD OR, 0.70 
[95% CI, 0.65–0.76], P=8×10−20).
Next, we compared the associations between geneti-
cally proxied ApoB lowering and ASCVD outcomes in 
gene-based analyses, identifying potential heteroge-
neous effects on PAD and CAD risk. We identified pro-
tective effects on CAD or PAD for 11 of 12 ApoB target 
genes (Figure 3B and Table XVI in the Data Supple-
ment). Although several associations did not achieve 
statistical significance for PAD specifically, associations 
were generally in the risk-decreasing direction, except 
for the HMGCR locus, which trended toward increased 
PAD risk (although 95% CIs did not exclude a small pro-
tective effect on PAD). Consistent with the overall poly-
genic analysis, genetically proxied ApoB lowering at the 
ABCG5, PCSK9, APOB, LDLR, and ANGPTL8 loci had 
significantly greater protective effects on CAD compared 
with PAD (ratio of effect estimates >1, FDR <0.05; Fig-
ure 3C). Results were similar, although with wider CIs, 
when we considered the MR-Egger method (Table XVI 
in the Data Supplement).
We also performed polygenic and gene-specific MR 
analyses to explore whether XS.VLDL.P–associated 
genes identified in the TWAS analysis were associated 
with PAD risk. In the polygenic analysis, ApoB lower-
ing proxied by genetic variants located within or near 
XS.VLDL.P–associated genes was associated with a 
reduced risk of PAD (OR, 0.89 per 1-SD reduction in 
ApoB [95% CI, 0.86–0.92]; P=3×10−11; Figure 4 and 
Table XVII in the Data Supplement). In gene-specific 
analyses, ApoB lowering at the CETP, NLRC5, and YIPF2 
loci were significantly associated with decreased PAD 
risk, whereas ApoB lowering at the ANKDD1B locus was 
associated with increased PAD risk (Figure 4). CIs were 
wider with the MR-Egger method (Table XVII in the Data 
Supplement), although the association remained signifi-
cant at the polygenic level.
Circulating Lp(a) and PAD Risk
Because previous studies have identified an associa-
tion between genetically predicted Lp(a) and CAD,28,31 









 XS.VLDL.P 0.912 0.0023 0.0012
 IDL.P 0.078 0.963 1
 L.LDL.P 0.023 0.999 1
 S.VLDL.P 0.022 0.901 1
 M.LDL.P 0.021 0.999 1
 XL.VLDL.P 0.021 0.996 1
 S.LDL.P 0.02 1 1
 XXL.VLDL.P 0.017 1 1
 L.VLDL.P 0.014 0.999 1
 M.VLDL.P 0.014 0.997 1
CAD
 L.LDL.P 0.613 0.008 0.04
 M.LDL.P 0.382 0.554 1
 IDL.P 0.071 0.614 1
 S.LDL.P 0.045 0.981 1
 XS.VLDL.P 0.036 0.294 1
 S.VLDL.P 0.027 0.765 1
 M.VLDL.P 0.023 0.9 1
 L.VLDL.P 0.016 0.948 1
 XL.VLDL.P 0.015 0.986 1
 XXL.VLDL.P 0.014 0.95 1
Ranking of most likely causal exposures among ApoB-containing lipid subfrac-
tions for PAD and CAD was prioritized using multivariable mendelian randomiza-
tion in the mendelian randomization bayesian model averaging framework. FDR-
corrected P values were derived with the Nyholt procedure of effective tests to 
account for the strong correlation among the subfractions. ApoB indicates apo-
lipoprotein B; FDR, false discovery rate; IDL.P, intermediate-density lipoprotein 
particles; L.LDL.P, large large-density lipoprotein particles; L.VLDL.P, large very-
large-density lipoprotein particles; M.LDL.P, medium large-density lipoprotein par-
ticles; M.VLDL.P, medium very-large-density lipoprotein particles; PAD, peripheral 
artery disease; S.LDL.P, small large-density lipoprotein particles; S.VLDL.P, small 
very-large-density lipoprotein particles; XL.VLDL.P, extralarge very-large-density 
lipoprotein particles; XS.VLDL.P, extra-small very-large-density lipoprotein par-
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we investigated the relationship between circulating 
Lp(a) and PAD risk. Unlike the other major lipopro-
tein-related traits that are genetically correlated and 
share a complex polygenic architecture, circulating 
Lp(a) levels are regulated primarily by genetic variants 
acting specifically at the LPA locus on chromosome 
6.32 Consistent with this architecture, we did not iden-
tify significant genetic correlations between Lp(a) and 
other lipoprotein-related traits (Table XVIII in the Data 
Supplement). In MR analyses, increases in genetically 
predicted Lp(a) were associated with increased risk 
of PAD [OR, 1.04 per 10–mg/dL increase in Lp(a) 
[95% CI, 1.03–1.04]; P=3×10−32], and the effect ap-
peared linear across the range of Lp(a) (Table XIX 
and Figure I in the Data Supplement). This associa-
tion was not attenuated in multivariable MR account-
ing for the associations of these genetic variants with 
ApoB (OR, 1.04 [95% CI, 1.03–1.04]; P=1.0×10−33). 
For comparison, genetically predicted Lp(a) was also 
associated with increased risk of CAD (OR, 1.06 
[95% CI, 1.05–1.06]; P=1×10−94). Genetically pre-
dicted Lp(a) was more strongly associated with CAD 
compared with PAD (ratio of effects, 1.62 [95% CI, 
1.35–1.98]; P<1×10−6).
DISCUSSION
We integrated several large genetic data sets and an ar-
ray of statistical genetics, molecular epidemiology, and 
bioinformatic techniques to uncover novel causal rela-
tionships between circulating lipoprotein-related traits 
and PAD, and we compared these findings with CAD. 
First, we identified ApoB as the primary major circulat-
ing lipoprotein-related trait responsible for risk of PAD, 
similar to CAD. Next, we prioritized XS.VLDL.P as the 
ApoB-associated subfraction most strongly associated 
with PAD risk, in contrast to CAD, for which L.LDL.P was 
the most strongly associated lipoprotein subfraction. We 
identified genes involved in the regulation of important 
ApoB-containing lipoprotein subfractions, which may 
represent directed targets for novel PAD prevention and 
treatment strategies. We explored the impact of ApoB 
lowering on PAD and uncovered the potential for the 
XS.VLDL.P pathway to be targeted to reduce PAD risk. 
Last, we identified an association between Lp(a) and 
PAD that is independent of ApoB.
These results highlight similarities and differences in 
the roles of circulating lipoproteins for PAD and CAD. 
Our primary analysis identified ApoB as the major 
Figure 2. Genes associated with circulating levels of extra-small very-low-density lipoprotein particle concentration  
(XS.VLDL.P) and large low-density lipoprotein particle concentration (L.LDL.P) lipoprotein subfractions.
Transcriptome-wide association studies were performed integrating liver gene expression data from Genotype-Tissue Expression version 8 
with genome-wide association study (GWAS) summary statistics for XS.VLDL.P and L.LDL.P to identify genes associated with circulating 
levels of each lipoprotein subfraction. A, Genes significantly (false discovery rate [FDR] <0.05) associated with either subfraction are labeled, 
and colors represent the subfraction associations. B, Bar plot depicts the number of unique and shared genes between the 2 subfractions. 
C, Forest plot depicts the z score for the difference in the effect magnitude for each gene on each subfraction (|βXS.VLDL.P|−|βL.LDL.P|). Dotted 
lines represent z scores of ±1.96, with point estimates outside this range representing significant (Pdiff<0.05) differential effects. Error bars 
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lipoprotein-related trait responsible for both PAD and 
CAD risk. This finding is consistent with a recent meta-
analysis of 22 studies (including 1892 PAD cases and 
30 937 controls) that found significantly higher ApoB 
levels among PAD cases compared with controls.33 A 
nested case-control study within the PHS (Physicians’ 
Health Study) similarly identified baseline ApoB levels 
(in addition to several other lipid fractions) as a sig-
nificant predictor of incident PAD.34 In contrast, a large 
observational study including 31 657 participants of 5 
prospective Finnish cohorts did not detect an associa-
tion between ApoB levels and incident PAD but may 
have been limited by a low incidence of PAD (498 
cases) and by defining PAD on the basis of hospitaliza-
tion codes.35 Similarly, while the WHS (Women’s Health 
Study) did not identify an association between baseline 
ApoB and incident PAD,5 differences in PAD case defi-
nitions, ascertainment, and demographics (incident PAD 
in WHS versus prevalent in MVP; women in WHS ver-
sus predominately men in MVP and PHS) may account 
for these differences. Our prioritization of ApoB as the 
most important lipoprotein-related risk factor for CAD 
is consistent with recent MR studies establishing ApoB 
as the primary risk factor for CAD.15,16 We also identi-
fied a modest but significant association between Lp(a) 
and PAD that was independent of ApoB, consistent with 
previous MR studies linking Lp(a) to CAD.28,36 In the set-
ting of strong epidemiological and genetic correlation 
between CAD and PAD, it is not surprising that these 
2 manifestations of ASCVD share ApoB and Lp(a) as 
common risk factors. However, we identified a stronger 
effect of ApoB on CAD than PAD, which has implica-
tions for risk stratification and treatment.
ApoB-containing particles exist on a spectrum of 
varying sizes, densities, and particle compositions, and 
identification of specific subfractions that contribute 
to different forms of ASCVD may have implications for 
pathophysiology, molecular mechanisms, risk stratifi-
cation, and treatment.37 Variability in the distribution of 
ApoB within lipoprotein subfractions may contribute to 
differential risk of PAD compared with CAD. Indeed, clini-
cal observations have suggested that type III hyperlipo-
proteinemia (familial dysbetalipoproteinemia), a disorder 
specifically associated with VLDL remnant particles, may 
be a greater risk factor for PAD than for CAD.37 In our 
genetic analyses of ApoB-containing lipoprotein sub-
fractions using MR-BMA, XS.VLDL.P was the primary 
ApoB-containing subfraction contributing to PAD risk. 
In contrast, L.LDL.P was the primary ApoB-containing 
subfraction contributing to CAD risk. These results are 
consistent with a recent observational study exploring 
the effect of circulating lipoproteins and metabolites on 
incident PAD and CAD among 31 657 participants of 5 
prospective Finnish cohorts that found a strong associa-
tion between XS.VLDL.P and incident PAD, with no sig-
nificant association between L.LDLP and incident PAD.35 
The primary effect of XS.VLDL.P on PAD implicates an 
important role for triglyceride-rich lipoproteins and rem-
Figure 3. Associations between genetically predicted apolipoprotein B (ApoB) levels and peripheral artery disease (PAD).
Estimates represent associations between genetically proxied ApoB and PAD or coronary artery disease (CAD) risk, scaled to the change in disease 
risk per 1-SD decrease in ApoB. Genetic variants used to proxy reductions in ApoB included only those located near of within genes important in 
ApoB metabolism. A, Polygenic analysis including all such variants. B, Gene-based analyses considering variants for each gene region. The dotted 
line with slope of 1 represents the scenario in which the association of genetically proxied ApoB with disease risk is equal for both CAD and PAD. C, 
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nant particles in the pathogenesis of PAD. This stands 
in contrast to the effect of L.LDL.P on CAD, which sug-
gests that LDL-associated lipoprotein fractions may play 
a more important role in the pathogenesis of CAD.
Epidemiologically, small (rather than large) LDL par-
ticles have traditionally been associated with CAD risk, 
serving as a marker of atherogenic dyslipidemia, par-
ticularly in the context of metabolic syndrome.38 Various 
mechanisms have been proposed to explain this relation-
ship, including increased ability of small LDL particles to 
penetrate the arterial wall and increased susceptibility to 
oxidation. While a recent systematic review and meta-
analysis found that both small dense LDL particles and 
concentration were associated with risk of CAD across 
21 studies representing >30 000 subjects, there was 
substantial heterogeneity across studies, and observa-
tional findings more broadly may be limited by residual 
environmental confounding.39 In contrast, 2 recent obser-
vational studies have suggested that remnant cholesterol 
is more strongly predictive of ASCVD events than other 
lipoprotein-related traits.40,41 The prioritization of L.LDL.P 
does not preclude the possibility that small LDL or rem-
nant particles also cause ASCVD. Whether small LDL or 
triglyceride-rich lipoproteins represent causal risk factors 
rather than a consequence of other metabolic derange-
ments and the specific mechanisms by which different 
ApoB-containing subfractions contribute to ASCVD risk 
require further study. A previous MR analysis proposed a 
mechanism by which remnant particles causally increase 
inflammation (as measured by C-reactive protein level), 
whereas no inflammatory effect was detected in the set-
ting of genetically proxied elevations in LDL-C.42
Although both PAD and CAD are manifestations of 
ASCVD, there are pathophysiological differences between 
the 2 diseases that may provide a basis for targeted 
treatment strategies.43 Observational and genetic studies 
have suggested that the influence on common cardio-
vascular risk factors may vary across ASCVD outcomes, 
for example, with smoking more strongly associated with 
PAD and blood pressure more strongly associated with 
CAD, among others.44–47 Similarly, although ApoB rep-
resents a common lipoprotein risk factor for PAD and 
CAD, we identified differences in predicted response 
to ApoB-lowering treatment, underscoring potential dif-
ferences in the role of circulating lipoproteins on these 
ASCVD outcomes. We demonstrate that although ApoB 
lowering is expected to have favorable effects on both 
PAD and CAD risk, the relative benefit is expected to 
be significantly greater for CAD risk reduction compared 
with PAD risk reduction. Although large randomized, con-
trolled trials, genetic studies, and observational evidence 
have highlighted the importance of LDL-C and ApoB-
lowering in reducing ASCVD outcomes overall, these 
studies have focused primarily on major adverse car-
diovascular events and CAD outcomes.7,48,49 Our results 
reveal that the ApoB-lowering effect of several clinically 
approved and clinical trial-stage drug targets is predicted 
to differ between PAD and CAD, a finding that may 
A
B
Figure 4. Associations between extra-small very-low-density lipoprotein particle concentration (XS.VLDL.P)–associated genes 
and peripheral artery disease (PAD).
Polygenic and gene-specific mendelian randomization (MR) were performed to estimate the association between the apolipoprotein B (ApoB)–
lowering effect of XS.VLDL.P–associated genes and PAD. Gene-specific MR examining the impact of ApoB-associated variants in or near (±200 
kb) each XS.VLDL.P–associated gene, with polygenic targets denoting the aggregate impact of variants in or near these genes. Odds ratios (ORs) 
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have implications for both drug discovery and treatment 
paradigms. Although we identified varied effects across 
ApoB-lowering targets, these results should not at this 
point be used to guide treatment decisions, and MR and 
clinical trial estimates of treatment effects may vary.50 
Although overall these results support guideline recom-
mendations for the use of ApoB-lowering medications to 
reduce PAD risk, our results also argue for PAD-specific 
outcomes to be measured in cardiovascular outcomes 
trials because the absence of a treatment effect for CAD 
(or a combined end point) may not exclude PAD-spe-
cific effects.1,49 For example, the CETP (cholesteryl ester 
transfer protein) inhibitor torcetrapib was associated with 
a substantial decrease in the incidence of PAD in a large, 
placebo-controlled phase III clinical trial, although it was 
overall associated with increased risk of cardiovascular 
morbidity and mortality.51 The ongoing PROMINENT 
study (Pemafibrate to Reduce Cardiovascular Outcomes 
by Reducing Triglycerides in Patients With Diabetes) will 
evaluate the impact of triglyceride-rich lipoprotein lower-
ing on major cardiovascular events with adjudicated PAD 
events as a secondary end point of the trial.52
Last, our polygenic and gene-based drug target 
analyses highlighted potential targets for directed treat-
ment strategies. Because lipid-lowering medications 
induce specific changes in the circulating lipoprotein 
profile, our results suggest that specific drug target 
identification may play an important role in identifying 
PAD-focused treatments.53 For example, genes associ-
ated with circulating XS.VLDL.P were enriched in path-
ways related to triglyceride-rich lipoprotein metabolism. 
Although our polygenic and gene-specific MR analy-
ses suggested that both currently available and pro-
posed ApoB-lowering therapies would be expected to 
reduce PAD risk, we used MR to further highlight the 
XS.VLDL.P pathway as a potentially novel therapeutic 
target. Whether these genes and pathways represent 
pharmacological targets that ultimately affect PAD out-
comes warrants further study.
Limitations
This study should be interpreted within the context of 
its limitations. First, this study focused on prevalent PAD 
outcomes ascertained from electronic health records. 
The effect of lipoprotein-related traits may vary across 
specific incident PAD outcomes, including intermittent 
claudication, rest pain, tissue loss, and amputation. Sec-
ond, PAD outcomes were studied among primarily male 
participants of the Veterans Affairs MVP, and although 
participants were of diverse ancestries, further studies 
among other populations are warranted to improve the 
generalizability of these findings. Third, MR effect esti-
mates reflect lifelong genetic exposures and may not ac-
curately reflect the magnitude of benefit of shorter-term 
pharmacological interventions.54 Similarly, although we 
did not detect pleiotropic effects in MR-Egger analyses, 
we cannot exclude the possibility that genetic variants 
located within targets of lipid-lowering therapies may in-
fluence other cardiometabolic traits. Thus, our drug tar-
get MR findings should not be used to guide clinical de-
cisions on lipid-lowering therapies at this stage. Fourth, 
when correlated exposures exist within a common path-
way, the MR-BMA method identifies the most proximate 
risk factor to the outcome. Circulating levels of each lipid 
fraction are composed of several subcomponents (eg, 
ApoB, triglycerides, and cholesterol are found in VLDL, 
intermediate-density lipoprotein, and LDL compartments 
and subfractions). Prioritization of ApoB over LDL-C for 
PAD and CAD risk does not nullify LDL-C as a causal 
risk factor but indicates that the effects of lipid-lowering 
therapies are likely to be proportional to the change in 
ApoB rather than LDL-C. Detailed MR analysis of other 
lipid subfractions may prioritize additional PAD risk fac-
tors and therapeutic targets. Last, larger population-
scale GWASs of circulating lipoprotein-related traits and 
subfractions may enable the development of more ro-
bust genetic instruments, which may provide additional 
insights into the relationships between circulating lipo-
protein-related traits and ASCVD.
Overall, this analysis of large genetic data sets identi-
fied ApoB as the primary causal lipoprotein-related risk 
factor for PAD. Diverse effects of ApoB-lowering drug 
targets and ApoB-containing lipoprotein subfractions 
on PAD compared with CAD suggest possible biological 
differences in the pathogenesis of these diseases, with 
gene expression analyses revealing potential targets for 
novel PAD therapies.
ARTICLE INFORMATION
Received January 17, 2021; accepted May 16, 2021.
Affiliations
Division of Cardiovascular Medicine (M.G.L.), Department of Medicine (M.G.L., 
K.-M.C., D.J.R.), Department of Surgery (V.M.W., S.M.D.), Institute for Translational 
Medicine and Therapeutics (D.J.R., B.F.V.), Department of Genetics (D.J.R., B.V.F.), 
and Department of Systems Pharmacology and Translational Therapeutics (B.V.F.), 
University of Pennsylvania Perelman School of Medicine, Philadelphia. Corporal 
Michael J. Crescenz VA Medical Center, Philadelphia, PA (M.G.L., K.-M.C., B.F.V., 
S.M.D.). MRC Biostatistics Unit (V.Z., S.B.), Department of Medical Genetics (L.B.), 
and BHF Cardiovascular Epidemiology Unit (S.B.), School of Clinical Medicine, Uni-
versity of Cambridge, UK. Department of Epidemiology and Biostatistics (V.Z.), De-
mentia Research Institute (V.Z.), and Department of Epidemiology and Biostatistics 
(D.G.), Imperial College London, UK. Medical Research Council Integrative Epide-
miology Unit, University of Bristol, UK (V.M.W.). Malcolm Randall VA Medical Center, 
Gainesville, FL (D.K.). Department of Surgery, University of Florida, Gainesville (D.K.). 
VA Informatics and Computing Infrastructure, Department of Veterans Affairs, Salt 
Lake City Health Care System, UT (J.L.). University of Utah School of Medicine, Salt 
Lake City (J.L.). Institute for Stroke and Dementia Research, University Hospital 
of Ludwig-Maximilians-University, Munich, Germany (R.M.). Vanderbilt Translational 
and Clinical Cardiovascular Research Center, Division of Cardiovascular Medicine, 
Vanderbilt University Medical Center, Nashville, TN (A.W.A.). The Alan Turing Insti-
tute, London, UK (L.B.). Division of Preventive Medicine, Brigham and Women’s 
Hospital, Harvard Medical School, Boston, MA (A.D.P.). Division of Cardiovascular 
Medicine, VA Boston Medical Center, MA (A.D.P.). Institute for Stroke and Dementia 
Research, University Hospital of Ludwig-Maximilians-University, Munich, Germany 
(M.D.). German Center for Neurodegenerative Diseases (DZNE), Munich, Germany 








Circulation. 2021;144:353–364. DOI: 10.1161/CIRCULATIONAHA.121.053797 August 3, 2021 363
Levin et al Lipoprotein-Related Traits and PAD Risk
Palo Alto VA Healthcare System, CA (P.S.T.). Department of Medicine, Division of 
Cardiovascular Medicine, and Stanford Cardiovascular Institute, Stanford University, 
Palo Alto, CA (P.S.T.). Clinical Pharmacology and Therapeutics Section, Institute for 
Infection and Immunity, St. George’s, University of London, UK (D.G.). Novo Nordisk 
Research Centre Oxford, Old Road Campus, UK (D.G.).
Acknowledgments
The authors thank the participants of the VA Million Veterans Program, UK Bio-
bank, CARDIoGRAMplusC4D, and NMR metabolomics studies.
Sources of Funding
This research is based on data from the MVP, Office of Research and Develop-
ment, Veterans Health Administration and was supported by award MVP003/
MVP028 (I01-BX003362). A list of MVP collaborators is included in the Data 
Supplement. This work was supported by US Department of Veterans Affairs 
grant IK2-CX001780 (Dr Damrauer). This publication does not represent the 
views of the Department of Veterans Affairs or the US government. Dr Zuber is 
supported by UK Dementia Research Institute at Imperial College London, which 
is funded by the Medical Research Council, Alzheimer’s Society, and Alzheimer’s 
Research UK (MC_PC_17114). Dr Aday is supported by NIH K23 HL151871. 
Dr Gill is supported by the British Heart Foundation Center of Research Excel-
lence (RE/18/4/34215) at Imperial College London and a National Institute for 
Health Research Clinical Lectureship at St. George’s, University of London (CL-
2020-16-001). Dr Burgess is supported by a Sir Henry Dale Fellowship jointly 
funded by the Wellcome Trust and the Royal Society (grant 204623/Z/16/Z).
Disclosures
Dr Damrauer receives research support to his institution from RenalytixAI and 
reports consulting fees from Calico Labs, all outside the current work. Dr Gill 
is employed part-time by Novo Nordisk. Dr Rader serves on scientific advisory 
boards for Alnylam, Novartis, Pfizer, and Verve and is a cofounder of Staten Bio-
technology. Dr Aday reports consulting fees from OptumCare outside the current 
work. The other authors report no conflicts.
Supplemental Material
Expanded Methods and Materials
Data Supplement Figure I
Data Supplement Excel File I (Data Supplement Tables I–XIX)
References 55–60
REFERENCES
 1. Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, 
Drachman DE, Fleisher LA, Fowkes FGR, Hamburg NM, Kinlay S, et al. 
2016 Lower extremity peripheral arterial disease guidelines. J Am Coll Car-
diol. 2017;69:e71–e126.
 2. Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res. 
2015;116:1509–1526. doi: 10.1161/CIRCRESAHA.116.303849
 3. Song P, Rudan D, Zhu Y, Fowkes FJI, Rahimi K, Fowkes FGR, Rudan I. 
Global, regional, and national prevalence and risk factors for peripheral ar-
tery disease in 2015: an updated systematic review and analysis. Lancet 
Glob Health. 2019;7:e1020–e1030.
 4. Aday AW, Everett BM. Dyslipidemia profiles in patients with peripheral artery 
disease. Curr Cardiol Rep. 2019;21:42. doi: 10.1007/s11886-019-1129-5
 5. Aday AW, Lawler PR, Cook NR, Ridker PM, Mora S, Pradhan AD. Lipopro-
tein particle profiles, standard lipids, and peripheral artery disease incidence. 
Circulation. 2018;138:2330–2341. doi: 10.1161/CIRCULATIONAHA. 
118.035432
 6. Duran EK, Aday AW, Cook NR, Buring JE, Ridker PM, Pradhan AD. Tri-
glyceride-rich lipoprotein cholesterol, small dense LDL cholesterol, and in-
cident cardiovascular disease. J Am Coll Cardiol. 2020;75:2122–2135. doi: 
10.1016/j.jacc.2020.02.059
 7. Aung PP, Maxwell HG, Jepson RG, Price JF, Leng GC. Lipid-lowering for 
peripheral arterial disease of the lower limb. Cochrane Database Systc Rev. 
2007;2007:CD000123. doi: 10.1002/14651858.CD000123.pub2
 8. Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, 
Ganna A, Chen J, Buchkovich ML, Mora S, et al; Global Lipids Genetics 
Consortium. Discovery and refinement of loci associated with lipid levels. 
Nat Genet. 2013;45:1274–1283. doi: 10.1038/ng.2797
 9. Kettunen J, Demirkan A, Würtz P, Draisma HH, Haller T, Rawal R, Vaarhorst 
A, Kangas AJ, Lyytikäinen LP, Pirinen M, et al. Genome-wide study for cir-
culating metabolites identifies 62 loci and reveals novel systemic effects of 
LPA. Nat Commun. 2016;7:11122. doi: 10.1038/ncomms11122
 10. Klarin D, Lynch J, Aragam K, Chaffin M, Assimes TL, Huang J, Lee KM, Shao 
Q, Huffman JE, Natarajan P, et al; VA Million Veteran Program. Genome-wide 
association study of peripheral artery disease in the Million Veteran Program. 
Nat Med. 2019;25:1274–1279. doi: 10.1038/s41591-019-0492-5
 11. Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, Kanoni S, Saleheen D, 
Kyriakou T, Nelson CP, Hopewell JC, et al. A comprehensive 1,000 Ge-
nomes-based genome-wide association meta-analysis of coronary artery 
disease. Nat Genet. 2015;47:1121–1130. doi: 10.1038/ng.3396
 12. Malik R, Chauhan G, Traylor M, Sargurupremraj M, Okada Y, Mishra A, 
Rutten-Jacobs L, Giese AK, van der Laan SW, Gretarsdottir S, et al; AFGen 
Consortium; Cohorts for Heart and Aging Research in Genomic Epidemi-
ology (CHARGE) Consortium; International Genomics of Blood Pressure 
(iGEN-BP) Consortium; INVENT Consortium; STARNET; BioBank Japan 
Cooperative Hospital Group; COMPASS Consortium; EPIC-CVD Consor-
tium; EPIC-InterAct Consortium; International Stroke Genetics Consor-
tium (ISGC); METASTROKE Consortium; Neurology Working Group of 
the CHARGE Consortium; NINDS Stroke Genetics Network (SiGN); UK 
Young Lacunar DNA Study; MEGASTROKE Consortium. Multiancestry 
genome-wide association study of 520,000 subjects identifies 32 loci as-
sociated with stroke and stroke subtypes. Nat Genet. 2018;50:524–537. 
doi: 10.1038/s41588-018-0058-3
 13. Burgess S, Foley CN, Zuber V. Inferring causal relationships between risk 
factors and outcomes from genome-wide association study data. Annu 
Rev Genomics Hum Genet. 2018;19:303–327. doi: 10.1146/annurev- 
genom-083117-021731
 14. Zuber V, Colijn JM, Klaver C, Burgess S. Selecting likely causal risk factors 
from high-throughput experiments using multivariable mendelian random-
ization. Nat Commun. 2020;11:29. doi: 10.1038/s41467-019-13870-3
 15. Zuber V, Gill D, Ala-Korpela M, Langenberg C, Butterworth A, Bottolo L, Burgess 
S. High-throughput multivariable mendelian randomization analysis prioritizes 
apolipoprotein B as key lipid risk factor for coronary artery disease [pub-
lished online November 1, 2020]. Int J Epidemiol. doi: 10.1093/ije/dyaa216. 
https://academic.oup.com/ije/article-lookup/doi/10.1093/ije/dyaa216
 16. Ference BA, Kastelein JJP, Ray KK, Ginsberg HN, Chapman MJ, Packard 
CJ, Laufs U, Oliver-Williams C, Wood AM, Butterworth AS, et al. Associa-
tion of triglyceride-lowering LPL variants and LDL-C-lowering LDLR vari-
ants with risk of coronary heart disease. JAMA. 2019;321:364–373. doi: 
10.1001/jama.2018.20045
 17. Gill D, Georgakis MK, Koskeridis F, Jiang L, Feng Q, Wei WQ, Theodoratou 
E, Elliott P, Denny JC, Malik R, et al. Use of genetic variants related to 
antihypertensive drugs to inform on efficacy and side effects. Circulation. 
2019;140:270–279. doi: 10.1161/CIRCULATIONAHA.118.038814
 18. Walker VM, Kehoe PG, Martin RM, Davies NM. Repurposing antihy-
pertensive drugs for the prevention of Alzheimer’s disease: a mende-
lian randomization study. Int J Epidemiol. 2020;49:1132–1140. doi: 
10.1093/ije/dyz155
 19. Schmidt AF, Finan C, Gordillo-Marañón M, Asselbergs FW, Freitag DF, Patel 
RS, Tyl B, Chopade S, Faraway R, Zwierzyna M, et al. Genetic drug target 
validation using mendelian randomisation. Nat Commun. 2020;11:3255. 
doi: 10.1038/s41467-020-16969-0
 20. Barbeira AN, Dickinson SP, Bonazzola R, Zheng J, Wheeler HE, Torres 
JM, Torstenson ES, Shah KP, Garcia T, Edwards TL, et al; GTEx Consor-
tium. Exploring the phenotypic consequences of tissue specific gene ex-
pression variation inferred from GWAS summary statistics. Nat Commun. 
2018;9:1825. doi: 10.1038/s41467-018-03621-1
 21. Gaziano JM, Concato J, Brophy M, Fiore L, Pyarajan S, Breeling J, 
Whitbourne S, Deen J, Shannon C, Humphries D, et al. Million Veteran Pro-
gram: a mega-biobank to study genetic influences on health and disease. J 
Clin Epidemiol. 2016;70:214–223. doi: 10.1016/j.jclinepi.2015.09.016
 22. Sanderson E, Davey Smith G, Windmeijer F, Bowden J. An examination 
of multivariable mendelian randomization in the single-sample and two-
sample summary data settings. Int J Epidemiol. 2019;48:713–727. doi: 
10.1093/ije/dyy262
 23. Burgess S, Thompson SG. Multivariable mendelian randomization: the use 
of pleiotropic genetic variants to estimate causal effects. Am J Epidemiol. 
2015;181:251–260. doi: 10.1093/aje/kwu283
 24. Ge SX, Jung D, Yao R. ShinyGO: a graphical gene-set enrichment 
tool for animals and plants. Bioinformatics. 2020;36:2628–2629. doi: 
10.1093/bioinformatics/btz931
 25. Li B, Leal SM. Methods for detecting associations with rare variants for 
common diseases: application to analysis of sequence data. Am J Hum 
Genet. 2008;83:311–321. doi: 10.1016/j.ajhg.2008.06.024
 26. Gill D, Georgakis MK, Walker VM, Schmidt AF, Gkatzionis A, Freitag DF, 



















August 3, 2021 Circulation. 2021;144:353–364. DOI: 10.1161/CIRCULATIONAHA.121.053797364
Levin et al Lipoprotein-Related Traits and PAD Risk
ization for studying the effects of perturbing drug targets. Wellcome Open 
Res. 2021;6:16. doi: 10.12688/wellcomeopenres.16544.2
 27. Slob EAW, Burgess S. A comparison of robust mendelian randomization 
methods using summary data. Genet Epidemiol. 2020;44:313–329. doi: 
10.1002/gepi.22295
 28. Burgess S, Ference BA, Staley JR, Freitag DF, Mason AM, Nielsen SF, 
Willeit P, Young R, Surendran P, Karthikeyan S, et al; European Prospec-
tive Investigation Into Cancer and Nutrition–Cardiovascular Disease 
(EPIC-CVD) Consortium. Association of LPA variants with risk of coro-
nary disease and the implications for lipoprotein(a)-lowering therapies: a 
mendelian randomization analysis. JAMA Cardiol. 2018;3:619–627. doi: 
10.1001/jamacardio.2018.1470
 29. Nyholt DR. A simple correction for multiple testing for single-nucleotide 
polymorphisms in linkage disequilibrium with each other. Am J Hum Genet. 
2004;74:765–769. doi: 10.1086/383251
 30. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke 
JP; STROBE Initiative. The Strengthening the Reporting of Observational 
Studies in Epidemiology (STROBE) statement: guidelines for reporting 
observational studies. PLoS Med. 2007;4:e296. doi: 10.1371/journal. 
pmed.0040296
 31. Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, Parish S, 
Barlera S, Franzosi MG, Rust S, et al; PROCARDIS Consortium. Genetic 
variants associated with Lp(a) lipoprotein level and coronary disease. N Engl 
J Med. 2009;361:2518–2528. doi: 10.1056/NEJMoa0902604
 32. Barlera S, Specchia C, Farrall M, Chiodini BD, Franzosi MG, Rust S, Green 
F, Nicolis EB, Peden J, Assmann G, et al; PROCARDIS Consortium. Mul-
tiple QTL influence the serum Lp(a) concentration: a genome-wide linkage 
screen in the PROCARDIS study. Eur J Hum Genet. 2007;15:221–227. doi: 
10.1038/sj.ejhg.5201732
 33. Forte F, Calcaterra I, Lupoli R, Orsini RC, Chiurazzi M, Tripaldella M, 
Iannuzzo G, Di Minno MND. Association of apolipoprotein levels 
with peripheral arterial disease: a meta-analysis of literature stud-
ies [published online September 18, 2020]. Eur J Prev Cardiol. doi: 
10.1093/eurjpc/zwaa029. https://academic.oup.com/eurjpc/article-lookup/ 
doi/10.1093/eurjpc/zwaa029
 34. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic ath-
erosclerosis: a comparison of C-reactive protein, fibrinogen, homo-
cysteine, lipoprotein(a), and standard cholesterol screening as predic-
tors of peripheral arterial disease. JAMA. 2001;285:2481–2485. doi: 
10.1001/jama.285.19.2481
 35. Tikkanen E, Jägerroos V, Rodosthenous R, Holmes MV, Sattar N, 
Ala-Korpela M, Jousilahti P, Lundqvist A, Perola M, Salomaa V, et al. Meta-
bolic biomarkers for peripheral artery disease compared with coronary ar-
tery disease: lipoprotein and metabolite profiling of 31,657 individuals from 
five prospective cohorts. medRxiv. Preprint posted online July 24, 2020. doi: 
https://doi.org/10.1101/2020.07.24.20158675
 36. Trinder M, Zekavat SM, Uddin MM, Pampana A, Natarajan P. Apolipopro-
tein B is an insufficient explanation for the risk of coronary disease as-
sociated with lipoprotein(a). Cardiovasc Res. 2021;117:1245–1247. doi: 
10.1093/cvr/cvab060
 37. Rader DJ, Kathiresan S. Disorders of lipoprotein metabolism. In: Jameson 
JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J, eds. Harrison’s 
Principles of Internal Medicine. 20th ed. McGraw-Hill Education; 2018.
 38. Xiao C, Dash S, Morgantini C, Hegele RA, Lewis GF. Pharmacological tar-
geting of the atherogenic dyslipidemia complex: the next frontier in CVD 
prevention beyond lowering LDL cholesterol. Diabetes. 2016;65:1767–
1778. doi: 10.2337/db16-0046
 39. Liou L, Kaptoge S. Association of small, dense LDL-cholesterol concentra-
tion and lipoprotein particle characteristics with coronary heart disease: a 
systematic review and meta-analysis. PLoS One. 2020;15:e0241993. doi: 
10.1371/journal.pone.0241993
 40. Balling M, Afzal S, Varbo A, Langsted A, Davey Smith G, Nordestgaard 
BG. VLDL cholesterol accounts for one-half of the risk of myocardial in-
farction associated with apoB-containing lipoproteins. J Am Coll Cardiol. 
2020;76:2725–2735. doi: 10.1016/j.jacc.2020.09.610
 41. Castañer O, Pintó X, Subirana I, Amor AJ, Ros E, Hernáez Á, Martínez-González 
MÁ, Corella D, Salas-Salvadó J, Estruch R, et al. Remnant cholesterol, not 
LDL cholesterol, is associated with incident cardiovascular disease. J Am 
Coll Cardiol. 2020;76:2712–2724. doi: 10.1016/j.jacc.2020.10.008
 42. Varbo A, Benn M, Tybjærg-Hansen A, Nordestgaard BG. Elevated remnant 
cholesterol causes both low-grade inflammation and ischemic heart dis-
ease, whereas elevated low-density lipoprotein cholesterol causes ischemic 
heart disease without inflammation. Circulation. 2013;128:1298–1309. doi: 
10.1161/CIRCULATIONAHA.113.003008
 43. Narula N, Olin JW, Narula N. Pathologic disparities between peripheral 
artery disease and coronary artery disease. Arterioscler Thromb Vasc Biol. 
2020;40:1982–1989. doi: 10.1161/ATVBAHA.119.312864
 44. Ding N, Sang Y, Chen J, Ballew SH, Kalbaugh CA, Salameh MJ, Blaha MJ, 
Allison M, Heiss G, Selvin E, et al. Cigarette smoking, smoking cessation, 
and long-term risk of 3 major atherosclerotic diseases. J Am Coll Cardiol. 
2019;74:498–507. doi: 10.1016/j.jacc.2019.05.049
 45. Levin MG, Klarin D, Assimes TL, Freiberg MS, Ingelsson E, Lynch J, Natarajan 
P, O’Donnell C, Rader DJ, Tsao PS, et al; VA Million Veteran Program. Ge-
netics of smoking and risk of atherosclerotic cardiovascular diseases: a 
mendelian randomization study. JAMA Netw Open. 2021;4:e2034461. doi: 
10.1001/jamanetworkopen.2020.34461
 46. Levin MG, Klarin D, Walker VM, Gill D, Lynch J, Hellwege JN, Keaton JM, 
Lee KM, Assimes TL, Natarajan P, et al; VA Million Veteran Program. Associ-
ation between genetic variation in blood pressure and increased lifetime risk 
of peripheral artery disease. Arterioscler Thromb Vasc Biol. 2021;41:2027–
2034. doi: 10.1161/ATVBAHA.120.315482
 47. Kannel WB. Risk factors for atherosclerotic cardiovascular outcomes in dif-
ferent arterial territories. J Cardiovasc Risk. 1994;1:333–339.
 48. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel 
RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, et al; American Col-
lege of Cardiology/American Heart Association Task Force on Practice 
Guidelines. 2013 ACC/AHA guideline on the treatment of blood choles-
terol to reduce atherosclerotic cardiovascular risk in adults: a report of 
the American College of Cardiology/American Heart Association Task 
Force on Practice Guidelines. Circulation. 2014;129(suppl 2):S1–S45. doi: 
10.1161/01.cir.0000437738.63853.7a
 49. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn 
EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, et al. 2019 ACC/
AHA guideline on the primary prevention of cardiovascular disease: a report 
of the American College of Cardiology/American Heart Association Task 
Force on Clinical Practice Guidelines. Circulation. 2019;140:e596–e646. 
doi: 10.1161/CIR.0000000000000678
 50. Burgess S, Butterworth A, Malarstig A, Thompson SG. Use of mendelian 
randomisation to assess potential benefit of clinical intervention. BMJ. 
2012;345:e7325. doi: 10.1136/bmj.e7325
 51. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, 
Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, et al; ILLUMINATE Inves-
tigators. Effects of torcetrapib in patients at high risk for coronary events. N 
Engl J Med. 2007;357:2109–2122. doi: 10.1056/NEJMoa0706628
 52. Pradhan AD, Paynter NP, Everett BM, Glynn RJ, Amarenco P, Elam M, 
Ginsberg H, Hiatt WR, Ishibashi S, Koenig W, et al. Rationale and design 
of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Tri-
glycerides in Patients with Diabetes (PROMINENT) study. Am Heart J. 
2018;206:80–93. doi: 10.1016/j.ahj.2018.09.011
 53. Kofink D, Eppinga RN, van Gilst WH, Bakker SJL, Dullaart RPF, van der Harst 
P, Asselbergs FW. Statin effects on metabolic profiles. Circulation: Cardio-
vascular Genetics. 2017;10:e001759.
 54. Davies NM, Holmes MV, Davey Smith G. Reading mendelian randomisation 
studies: a guide, glossary, and checklist for clinicians. BMJ. 2018;362:k601. 
doi: 10.1136/bmj.k601
 55. Zuber V, Gill D, Ala-Korpela M, Langenberg C, Butterworth A, Bottolo L, 
Burgess S. High-throughput multivariable Mendelian randomization analysis 
prioritizes apolipoprotein B as key lipid risk factor for coronary artery dis-
ease. Ing J Epidemiol. 2020. doi: 2020.02.10.20021691.
 56. Staples J, Qiao D, Cho MH, Silverman EK, Nickerson DA, Below JE; University 
of Washington Center for Mendelian Genomics. PRIMUS: rapid reconstruc-
tion of pedigrees from genome-wide estimates of identity by descent. Am J 
Hum Genet. 2014;95:553–564. doi: 10.1016/j.ajhg.2014.10.005
 57. Ioannidis NM, Rothstein JH, Pejaver V, Middha S, McDonnell SK, Baheti S, 
Musolf A, Li Q, Holzinger E, Karyadi D, et al. REVEL: an ensemble method 
for predicting the pathogenicity of rare missense variants. Am J Hum Genet. 
2016;99:877–885. doi: 10.1016/j.ajhg.2016.08.016
 58. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, 
Collins RL, Laricchia KM, Ganna A, Birnbaum DP, et al; Genome Aggre-
gation Database Consortium. The mutational constraint spectrum quanti-
fied from variation in 141,456 humans. Nature. 2020;581:434–443. doi: 
10.1038/s41586-020-2308-7
 59. McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Thormann A, Flicek P, 
Cunningham F. The Ensembl variant effect predictor. Genome Biol. 
2016;17:122. doi: 10.1186/s13059-016-0974-4
 60. Zhan X, Hu Y, Li B, Abecasis GR, Liu DJ. RVTESTS: an efficient and com-
prehensive tool for rare variant association analysis using sequence data. 




 http://ahajournals.org by on Septem
ber 15, 2021
